


## KU-177

Cat. No.:	HY-151335
CAS No.:	1160952-43-1
Molecular Formula:	C <sub>27</sub> H <sub>23</sub> NO <sub>8</sub>
Molecular Weight:	489.47
Target:	HSP
Pathway:	Cell Cycle/DNA Damage; Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	<p>KU-177 is a potent inhibitor of Hsp90 ATPase homologue 1 (Aha1), ablates Aha1-driven enhancement of Hsp90-dependent tau aggregation. KU-177 also disrupts Aha1/Hsp90 interactions (IC<sub>50</sub>=4.08 μM) without inhibition of Hsp90's ATPase activity. KU-177 can be used for tauopathies research<sup>[1][2]</sup>.</p>																	
<b>IC<sub>50</sub> &amp; Target</b>	HSP90																	
<b>In Vitro</b>	<p>KU-177 (50 μM; 48 h) hampers the proliferation of flow MRD-positive cells in both primary multiple myeloma (MM) and recurrent MM patient samples<sup>[1]</sup>.</p> <p>KU-177 (30 μM; 48 h) inhibits proteasome activity in AHSA1 WT/OE cells, PSMD2 WT/OE cells and ANBL6 WT/DR cells<sup>[1]</sup>.</p> <p>KU-177 abrogates the cellular proliferation and PI resistance induced by elevated AHSA1, and decreases the expression of CDK6 and PSMD2<sup>[1]</sup>.</p> <p>KU-177 (25 μM; 30 min; 37 °C) inhibits recombinant P301L tau aggregation without inhibiting Hsp90 to refold luciferase<sup>[2]</sup>.</p> <p>KU-177 (10 μM; 24 h) exhibits the ability to disrupt interactions between Aha1 and Hsp90 in SH-SY5Y neuroblastoma cells and SK-BR-3 breast cancer cells, without significantly inhibition on Hsp90 client protein (Her2)<sup>[2]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Proliferation Assay<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>ARP1 and H929 WT and AHSA1-OE cells</td> </tr> <tr> <td>Concentration:</td> <td>1 nM-100 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24, 48, 72 hours</td> </tr> <tr> <td>Result:</td> <td>Decreased multiple myeloma (MM) cell proliferation and PI resistance induced by AHSA1/HSP90 in vitro.</td> </tr> </table> <p>Cell Proliferation Assay<sup>[2]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>SH-SY5Y neuroblastoma cells and Her2 overexpressing SK-BR-3 breast cancer cells</td> </tr> <tr> <td>Concentration:</td> <td>10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 hours</td> </tr> <tr> <td>Result:</td> <td>Didn't induce the degradation of Hsp90 client proteins Her2 (in SK-BR-3 cells), Cdk6, or</td> </tr> </table>		Cell Line:	ARP1 and H929 WT and AHSA1-OE cells	Concentration:	1 nM-100 μM	Incubation Time:	24, 48, 72 hours	Result:	Decreased multiple myeloma (MM) cell proliferation and PI resistance induced by AHSA1/HSP90 in vitro.	Cell Line:	SH-SY5Y neuroblastoma cells and Her2 overexpressing SK-BR-3 breast cancer cells	Concentration:	10 μM	Incubation Time:	24 hours	Result:	Didn't induce the degradation of Hsp90 client proteins Her2 (in SK-BR-3 cells), Cdk6, or
Cell Line:	ARP1 and H929 WT and AHSA1-OE cells																	
Concentration:	1 nM-100 μM																	
Incubation Time:	24, 48, 72 hours																	
Result:	Decreased multiple myeloma (MM) cell proliferation and PI resistance induced by AHSA1/HSP90 in vitro.																	
Cell Line:	SH-SY5Y neuroblastoma cells and Her2 overexpressing SK-BR-3 breast cancer cells																	
Concentration:	10 μM																	
Incubation Time:	24 hours																	
Result:	Didn't induce the degradation of Hsp90 client proteins Her2 (in SK-BR-3 cells), Cdk6, or																	

pAktS473 (in SHSY5Y cells), nor induced the expression of Hsp70, a marker of the heat shock response.

#### In Vivo

KU-177 (1 mg/kg; i.p.; twice a week; 4 weeks), inhibits tumor growth and extends the survival of 5TMM3VT MM mice without significant toxicity. KU-177 shows stronger efficacy in vivo, combined with [Bortezomib](#) (HY-10227) (1 mg/kg; i.p.)<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	5TMM3VT mouse model (6-8 weeks old, C57BL/KaLwrij mice) <sup>[1]</sup>
Dosage:	1 mg/kg
Administration:	Intraperitoneal injection; twice a week; sacrificed mice with hindlimb weakness immediately, about 4-5 weeks
Result:	Inhibited the xenograft tumor growth of both ANBL6 WT/BTZ-DR cells. Didn't induce histopathological abnormalities or lesions in main organs including heart, liver, spleen, lung and kidney.

## REFERENCES

[1]. Gu C, et al. AHS1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma. J Exp Clin Cancer Res. 2022 Jan 6;41(1):11.

[2]. Keegan BM, et al. Synthesis and Evaluation of Small Molecule Disruptors of the Aha1/Hsp90 Complex for the Reduction of Tau Aggregation. ACS Med Chem Lett. 2022 Apr 15;13(5):827-832.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA